Case Reports in Oncology最新文献

{"title":"Gastric Cancer Treated with 5-Fluorouracil following Discontinuation of Adjuvant S1 plus Docetaxel and Capecitabine plus Oxaliplatin due to Drug-Induced Acute Pancreatitis: A Case Report.","authors":"Yumi Takamori, Yu Aoki, Hiroaki Miyake, Yumi Amano, Kota Tanuma, Atsushi Nakazawa, Shota Hoshino, Fumiki Toriumi, Shigemichi Hirose, Shinsuke Funakoshi","doi":"10.1159/000552401","DOIUrl":"10.1159/000552401","url":null,"abstract":"<p><strong>Introduction: </strong>Drug-induced acute pancreatitis (DIAP) is a rare cause of acute pancreatitis, accounting for approximately 3-5% of cases, and reports of chemotherapy-induced pancreatitis remain limited.</p><p><strong>Case presentation: </strong>Herein, we present the case of a 68-year-old man who developed DIAP during adjuvant chemotherapy with S-1 plus docetaxel and later with capecitabine plus oxaliplatin following surgery for gastric cancer. A drug-induced lymphocyte stimulation test (DLST) was conducted to identify the suspected agents, yielding positive results for S-1 and capecitabine, whereas docetaxel and oxaliplatin were negative. Unexpectedly, the DLST result for 5-fluorouracil was negative. Based on these findings, adjuvant chemotherapy was switched to 5-fluorouracil plus leucovorin, which was successfully continued without recurrence of pancreatitis. Shortly thereafter, the patient was diagnosed with recurrent gastric cancer. However, palliative chemotherapy with a 5-fluorouracil-based regimen was safely continued.</p><p><strong>Conclusion: </strong>Although DIAP can be fatal, the DLST may help identify the suspected causative drug and contribute to decision-making in important clinical situations such as cancer treatment.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"874-881"},"PeriodicalIF":0.7,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13341106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete Response in Metastatic Rectal Cancer with Hepatic and Pulmonary Metastases Treated with Second-Line FOLFIRI plus Ramucirumab: A Case Report.","authors":"Makoto Hasegawa, Hirokazu Okayama, Yuki Kitabori, Naoto Yamauchi, Takahiro Nakajima, Susumu Matsumoto, Naoki Sato, Motonobu Saito, Koji Kono","doi":"10.1159/000551538","DOIUrl":"10.1159/000551538","url":null,"abstract":"<p><strong>Introduction: </strong>In metastatic colorectal cancer (CRC), achieving complete response (CR) through chemotherapy alone is exceedingly rare. We report a case of metastatic CRC that achieved CR following second-line treatment with FOLFIRI plus ramucirumab after disease progression on first-line FOLFOX plus panitumumab therapy.</p><p><strong>Case presentation: </strong>A 61-year-old woman was diagnosed with stage IVB rectal cancer with synchronous liver, lung, and lateral lymph node metastasis (<i>KRAS/BRAF</i> wild-type, microsatellite stable, and HER2-negative). Following first-line FOLFOX plus panitumumab, regression was observed in the rectal lesion and liver metastasis, but one pulmonary nodule progressed. The regimen was switched to second-line FOLFIRI plus ramucirumab. Subsequently, a complete radiological response was observed in all lesions, and a biopsy of the rectal scar confirmed no malignancy. Considering the tumor heterogeneity and surgical morbidity, we engaged in shared decision-making with the patient and adopted a watch-and-wait strategy. The patient received consolidation chemotherapy and remains recurrence-free for 6 months after achieving CR.</p><p><strong>Conclusion: </strong>We report a rare case in which second-line FOLFIRI plus ramucirumab led to a CR in metastatic CRC, even after progression on anti-epidermal growth factor receptor therapy. In the present case, a watch-and-wait strategy was selected to prioritize organ preservation. Given the lack of consensus, further investigation is required to define the optimal strategy for patients achieving CR.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"704-711"},"PeriodicalIF":0.7,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148269776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growing Teratoma Syndrome Arising from a Pineal Mixed Germ Cell Tumor in a 12-Year-Old Boy.","authors":"Mandana Tasbihi, Guive Sharifi, Sahar Arbab Solimani, Morteza Ashrafi, Mahyar Nourian, Naghmeh Zamani, Alireza Sadeghipour, Bahar Moeini","doi":"10.1159/000552514","DOIUrl":"10.1159/000552514","url":null,"abstract":"<p><strong>Introduction: </strong>Pineal region tumors in children are rare and present significant diagnostic and therapeutic challenges due to their deep location, varied histology, and overlapping radiologic features. Mixed germ cell tumors (MGCTs) are particularly rare and may demonstrate complex clinical behavior.</p><p><strong>Case presentation: </strong>We report the case of a 12-year-old boy who presented in August 2024 with progressive headache and nausea. Brain magnetic resonance imaging (MRI) revealed a large pineal mass. Biopsy with endoscopic third ventriculostomy revealed an MGCT composed of 90% immature teratoma and 10% germinoma, with a Ki-67 index of 25%. Serum alpha-fetoprotein (AFP) was mildly elevated (23.2 ng/mL), while beta-human chorionic gonadotropin levels were normal. The patient received six cycles of chemotherapy according to the ACNS1123 protocol for non-germinomatous germ cell tumors. The MRI after chemotherapy showed increased tumor size with cystic/necrotic components and normalization of AFP. Subsequent surgical resection revealed a mature teratoma without malignant elements, consistent with growing teratoma syndrome (GTS). Notably, the Ki-67 index had decreased from 25% at diagnosis to 5% after resection. Given the initial histology and lack of cerebrospinal fluid analysis, adjuvant craniospinal irradiation of 36 Gy with a 54-Gy boost to the tumor bed was delivered according to ACNS0122.</p><p><strong>Conclusion: </strong>The patient tolerated treatment well and remains in good clinical and radiological condition. This case underscores the importance of recognizing GTS and individualizing treatment in pediatric pineal MGCTs.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"950-958"},"PeriodicalIF":0.7,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13391081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accelerated Bilateral Cataract Progression during Olaparib plus Bevacizumab Maintenance Therapy for High-Grade Serous Fallopian Tube Carcinoma: A Case Report.","authors":"Wataru Saito, Kuniaki Ota, Hana Okamoto, Mitsuru Shiota, Koichiro Shimoya, Yoshiaki Ota","doi":"10.1159/000551721","DOIUrl":"10.1159/000551721","url":null,"abstract":"<p><strong>Background: </strong>Primary peritoneal carcinoma and high-grade serous fallopian tube carcinoma share histopathologic and molecular characteristics with high-grade serous ovarian carcinoma and are treated according to similar therapeutic principles. Poly (ADP-ribose) polymerase (PARP) inhibitors, particularly olaparib, have become central to maintenance therapy, frequently administered with the anti-VEGF agent bevacizumab. Although olaparib is generally well tolerated, ocular toxicities such as cataract formation have not been documented in clinical trials or pharmacovigilance reports, and detailed descriptions are lacking.</p><p><strong>Case presentation: </strong>We report a 66-year-old woman with FIGO stage IIIC high-grade serous carcinoma of the fallopian tube with BRCA mutation and homologous recombination deficiency. After neoadjuvant chemotherapy with paclitaxel, carboplatin, and bevacizumab, followed by interval debulking surgery and postoperative chemotherapy, she achieved a complete response and began maintenance therapy with bevacizumab plus olaparib. After three cycles, she developed rapidly progressive visual impairment in the right eye. Ophthalmologic evaluation revealed a hypermature (Morgagnian-type) cataract with partial liquefaction requiring phacoemulsification with intraocular lens implantation. At the initial ophthalmologic examination, a contralateral mature cataract was also identified but was asymptomatic. Approximately 1 month after right eye surgery, the left eye developed symptomatic visual decline, necessitating cataract extraction. Postoperative recovery of both eyes was excellent.</p><p><strong>Discussion: </strong>To our knowledge, this is the first report describing bilateral accelerated cataract progression during olaparib therapy, particularly in combination with bevacizumab. While causality cannot be confirmed, the rapid onset, bilateral involvement, and temporal association with therapy suggest a potential treatment-related effect. Possible mechanisms include cytokine dysregulation, oxidative stress, and exacerbation of subclinical lens pathology.</p><p><strong>Conclusion: </strong>This case highlights a previously unreported ocular adverse event associated with combined PARP inhibitor and anti-VEGF maintenance therapy. Clinicians should maintain vigilance for visual symptoms and consider periodic ophthalmologic monitoring in patients receiving prolonged olaparib-based therapy.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"796-804"},"PeriodicalIF":0.7,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148315950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toripalimab in Metastatic Renal Collecting Duct Carcinoma: A Case Report.","authors":"Yi Wu, Chao Wang, Shuang Gao, Xiaogang Li","doi":"10.1159/000552402","DOIUrl":"10.1159/000552402","url":null,"abstract":"<p><strong>Introduction: </strong>Collecting duct carcinoma (CDC), a rare and highly aggressive subtype of renal cell carcinoma (RCC), is often associated with poor prognosis due to its resistance to conventional therapies. Although platinum-based chemotherapy is conventionally regarded as the first-line treatment of metastatic CDC, its clinical benefits are limited. Emerging evidence suggests that CDC shares immunophenotypic and genomic features with urothelial carcinoma, providing a rationale for investigating immune checkpoint inhibitors.</p><p><strong>Case presentation: </strong>We report the case of a 55-year-old male patient with postoperative metastatic CDC exhibiting a urothelial carcinoma-like immunophenotype. The patient presented with gross hematuria and left flank pain, and imaging revealed a large left renal mass with regional lymph node and pulmonary metastases. Histopathology confirmed CDC, characterized by high nuclear atypia, extensive necrosis, and high Ki-67 proliferation. First-line gemcitabine-cisplatin chemotherapy was discontinued due to grade III gastrointestinal toxicity, leading to imitation of second-line treatment with toripalimab, a programmed death protein 1 (PD-1) inhibitor. The patient achieved a complete response after six cycles of toripalimab, confirmed by the complete resolution of bilateral pulmonary metastases. Immune-related adverse events were managed with temporary treatment interruption, prednisone, and L-thyroxine therapy. Currently, the patient has maintained a progression-free survival of 24 months.</p><p><strong>Conclusion: </strong>This case demonstrates the complete response of metastatic CDC to toripalimab, despite negative PD-L1 expression. This outcome highlights the role of CD8+ T-cell infiltration and IFN-γ pathway activation within the tumor microenvironment in treatment response and the potential efficacy of PD-1 inhibition as a viable therapeutic strategy for this aggressive RCC subtype.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1005-1011"},"PeriodicalIF":0.7,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13399963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reversal of Radioiodine-Induced Azoospermia in Thyroid Cancer: A Case Report.","authors":"Haiqing Deng, Jun Zhang","doi":"10.1159/000552398","DOIUrl":"10.1159/000552398","url":null,"abstract":"<p><strong>Introduction: </strong>Radioiodine-131 (¹³¹I) is a commonly used adjuvant therapy following surgery for differentiated thyroid cancer. The nonspecific radiation damage may affect the male reproductive system, impacting sperm quality. However, reports of azoospermia are rare.</p><p><strong>Case presentation: </strong>A 26-year-old male patient with papillary thyroid carcinoma underwent cumulative 14.06 GBq ¹³¹I ablation therapy postoperatively. Eight months post-treatment, he was diagnosed with azoospermia due to planned conception. After ruling out congenital factors, ¹³¹I-related iatrogenic injury was considered. Sperm were detected again in a semen analysis 13 months after treatment completion. Subsequently, successful natural conception occurred, and the spouse delivered a healthy infant vaginally.</p><p><strong>Conclusion: </strong>¹³¹I therapy may induce azoospermia. However, the injury may be reversible. Clinicians should monitor reproductive risks in young patients and conduct follow-up evaluations.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"882-887"},"PeriodicalIF":0.7,"publicationDate":"2026-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13341095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged Survival in Metastatic Pancreatic Acinar Cell Carcinoma Treated with Hepatic Arterial Infusion of Oxaliplatin: A Case Report with Longitudinal Molecular Profiling.","authors":"Juliette Dubois, Mehdi Kaassis, Antoine Bouvier, Louis Besnier, Sovannarith Roeun, Victor Simmet","doi":"10.1159/000552399","DOIUrl":"10.1159/000552399","url":null,"abstract":"<p><strong>Introduction: </strong>Pancreatic acinar cell carcinoma (PACC) is a rare malignancy, representing 1-2% of pancreatic cancers. Although it generally has a better prognosis than ductal adenocarcinoma, optimal systemic management remains undefined. Hepatic arterial infusion (HAI) of chemotherapy has shown efficacy in colorectal liver metastases but is rarely reported in pancreatic cancer.</p><p><strong>Case presentation: </strong>We present a 36-year-old man diagnosed with metastatic PACC after developing abdominal pain and hepatomegaly. Imaging revealed a pancreatic tail mass and multiple liver metastases. After an initial partial response to FOLFIRINOX followed by several systemic regimens, the patient received a novel combination of intravenous 5-fluorouracil and HAIs of oxaliplatin. This strategy allowed a good hepatic response, and the patient had the administration of approximately 60 oxaliplatin-based cycles. The patient was included in a phase II trial thanks to serial molecular analyses that demonstrated progressive genomic evolution, with losses of RB1, PTEN, MTAP, CDKN2A/2B, and SMAD4.</p><p><strong>Conclusion: </strong>This case illustrates a rare metastatic PACC achieving prolonged survival through local control at the hepatic level, thanks to 42 cycles of HAI of oxaliplatin. It suggests that HAI may represent a feasible and effective regional strategy for selected patients with predominant liver involvement. The longitudinal molecular profiling shows the importance of re-biopsy to detect emerging actionable alterations and guide inclusion in targeted clinical trials.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"888-895"},"PeriodicalIF":0.7,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13345621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia at Initial Presentation: A Case Report and Review of the Literature.","authors":"Motaz Almahmood, Elmustafa Abdalla, Amin Saied, Dina Soliman, Ibrahim Almahdi A Ganwo, Feryal Ibrahim, Shehab Fareed","doi":"10.1159/000552419","DOIUrl":"10.1159/000552419","url":null,"abstract":"<p><strong>Introduction: </strong>Concurrent chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) in the same patient are rare and may be overlooked when leukocytosis is attributed to a single hematologic process. We report a case of synchronous CML and CLL identified at initial presentation, highlighting the diagnostic value of integrating morphology, immunophenotyping, cytogenetics, and molecular testing.</p><p><strong>Case presentation: </strong>A 44-year-old man presented with progressive weight loss and back pain and was found to have leukocytosis with neutrophilia, absolute lymphocytosis, eosinophilia, and basophilia. Peripheral blood smear and flow cytometry supported CLL, whereas reverse-transcription polymerase chain reaction and cytogenetics demonstrated e13a2 BCR::ABL1 and t(9;22)(q34;q11.2), confirming concomitant CML in chronic phase. Bone marrow examination showed hypercellularity with granulocytic hyperplasia and nodular lymphoid infiltrates, and fluorescence in situ hybridization detected 13q14.3 deletion in the lymphoid clone. Imatinib 400 mg daily was initiated but was replaced with dasatinib 100 mg daily because of intolerance. At 14 months of follow-up, the patient remained clinically stable on dasatinib, with early molecular response at 3 months and major molecular response at 12 months, while the CLL remained under observation without indication for CLL-directed therapy.</p><p><strong>Conclusion: </strong>This case highlights the diagnostic complexity of synchronous hematologic malignancies and the importance of comprehensive multimodal evaluation when clinical, morphologic, and laboratory findings are not fully explained by a single diagnosis. Treating the clinically dominant clone while monitoring the second clone may be appropriate when the latter is asymptomatic.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"671-678"},"PeriodicalIF":0.7,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Presentation of Palpable Bilateral Male Breast Cancer: A Case Report.","authors":"Morgan Malof, Alexandra McMillan, Flor Jasmin Torres, Joyce Moore","doi":"10.1159/000552472","DOIUrl":"10.1159/000552472","url":null,"abstract":"<p><strong>Introduction: </strong>We present a case on bilateral invasive ductal carcinoma in a male patient who presented with two palpable masses with one side initially attributed to gynecomastia.</p><p><strong>Case presentation: </strong>The patient underwent left breast lumpectomy and sentinel lymph node biopsy and right breast excisional biopsy. Postoperatively, pathology confirmed bilateral invasive carcinoma with one out of eight positive lymph nodes in the left breast. This patient did not undergo further procedures and was established with medical and radiation oncologists. After discussion with the patient and multidisciplinary team, it was decided that chemotherapy and radiation would not benefit this patient. The patient is following up regularly in 3 months postoperatively followed by 6-month intervals and is taking tamoxifen to aid in prevention of recurrence.</p><p><strong>Conclusion: </strong>The presentation of this case contributes to current breast cancer treatment and diagnosis, particularly in subset male population with an atypical presentation and unexpected diagnosis involving both breasts.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"896-903"},"PeriodicalIF":0.7,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13345620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Orbital and Parotid Metastases from Nasopharyngeal Carcinoma: A Rare Case Presentation and Review of the Literature.","authors":"Shmokh Alsalamah, Sultan Alsumairi, Malak Almalki, Majed Pharaon, Mohammed Alessa","doi":"10.1159/000551478","DOIUrl":"10.1159/000551478","url":null,"abstract":"<p><strong>Introduction: </strong>Nasopharyngeal carcinoma (NPC) is a rare, yet aggressive malignancy characterized by various clinical presentations. Metastasis to the orbital and parotid regions presents diagnostic challenges and adds complexity to the management.</p><p><strong>Case presentation: </strong>Herein, we present a case of a 23-year-old male diagnosed with non-keratinizing undifferentiated NPC, initially presenting with orbital metastasis followed by parotid gland involvement shortly after completion of chemoradiotherapy. The patient underwent surgical intervention preceded by chemoradiotherapy, resulting in complete remission without recurrence over a 12-month follow-up period.</p><p><strong>Conclusion: </strong>This case reinforces the critical importance of vigilant long-term surveillance in high-risk NPC patients with symptom-directed and risk-adapted surveillance approaches.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"685-694"},"PeriodicalIF":0.7,"publicationDate":"2026-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13268621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148263392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}